SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

  • STATUS
    Not Recruiting
  • participants needed
    120
  • sponsor
    Juventas Therapeutics, Inc.
Updated on 21 January 2021
arteriopathy
endovascular intervention
vascular disease
gangrene
peripheral arterial diseases
endovascular procedure
revascularisation

Summary

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.

Details
Condition Peripheral vascular disease, peripheral arterial disease
Treatment Placebo, JVS-100
Clinical Study IdentifierNCT02544204
SponsorJuventas Therapeutics, Inc.
Last Modified on21 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note